Article
Multidisciplinary Sciences
Hye Eun Park, Seung-Yeon Yoo, Nam-Yun Cho, Jeong Mo Bae, Sae-Won Han, Hye Seung Lee, Kyu Joo Park, Tae-You Kim, Gyeong Hoon Kang
Summary: Studies have shown that the prognostic effect of KRAS mutations on colorectal cancers varies depending on the type of mutation, with G12D/V mutations associated with shorter recurrence-free survival. Other codon 12 mutations and codon 13 mutations exhibit different trends.
SCIENTIFIC REPORTS
(2021)
Article
Oncology
Frank A. Sinicrope, Sakti Chakrabarti, Pierre Laurent-Puig, Luke Huebner, Thomas C. Smyrk, Josep Tabernero, Enrico Mini, Richard M. Goldberg, Aziz Zaanan, Gunnar Folprecht, Jean Luc Van Laethem, Karine Le Malicot, Qian Shi, Steven R. Alberts, Julien Taieb
Summary: This study stratified patients with stage III colon cancer and found that sidedness and BRAF/MMR contributed the most to survival outcomes among high-risk tumors, while mutant KRAS was associated with poor prognosis in both low and high-risk tumors.
EUROPEAN JOURNAL OF CANCER
(2021)
Article
Multidisciplinary Sciences
Gianluca Tomasello, Michele Ghidini, Barbara Galassi, Francesco Grossi, Andrea Luciani, Fausto Petrelli
Summary: In patients with stage III MSI-H/dMMR CRC, adjuvant chemotherapy is associated with a significant improvement in overall survival (OS), but does not significantly impact disease-free survival (DFS). This suggests that MSI-H/dMMR status is a predictive factor for benefit from postoperative chemotherapy in stage III CRC.
SCIENTIFIC REPORTS
(2022)
Article
Oncology
Xin Chen, Junhao Tu, Xiaolan Xu, Wen Gu, Lei Qin, Haixin Qian, Zhenyu Jia, Chuntao Ma, Yinkai Xu
Summary: This study found that adjuvant chemotherapy in elderly patients with stage III colon cancer can reduce cancer-specific mortality rate, but the benefit of chemotherapy in stage II colon cancer patients is suboptimal.
FRONTIERS IN ONCOLOGY
(2022)
Article
Oncology
Lana Khalil, Xingyu Gao, Jeffrey M. Switchenko, Olatunji B. Alese, Mehmet Akce, Christina Wu, Maria Diab, Bassel F. El-Rayes, Walid L. Shaib
Summary: This age group-based study examines the impact of adjuvant therapy in patients older than 70 with colon cancer. The study suggests that multi-agent chemotherapy may have better survival outcomes compared to single-agent chemotherapy in this age group.
Article
Oncology
Linjie Zhang, Yuxiang Deng, Songran Liu, Weili Zhang, Zhigang Hong, Zhenhai Lu, Zhizhong Pan, Xiaojun Wu, Jianhong Peng
Summary: This study aimed to confirm the prognostic value of lymphovascular invasion (LVI) and perineural invasion (PNI) in stage III colon cancer patients and identify patients who could benefit from a complete duration of adjuvant chemotherapy. The results showed that LVI has better prognostic value in stage III colon cancer patients, while PNI only predicts 3-year disease-free survival without significant impact on 3-year overall survival. Furthermore, LVI is also an effective indicator for adjuvant chemotherapy duration.
Article
Gastroenterology & Hepatology
Luv N. Hajirawala, Yong Yi, Brian C. Herritt, Morgan E. Laurent, Aaron L. Klinger, Guy R. Orangio, Kurt G. Davis, Jeffrey S. Barton
Summary: This study found that multiple high-risk features in stage II colon cancer are associated with worse survival. Moreover, chemotherapy has a negative impact on cause-specific survival in patients with stage II disease.
DISEASES OF THE COLON & RECTUM
(2023)
Article
Oncology
Meijiao Zhou, Trevor D. Thompson, Hui-Yi Lin, Vivien W. Chen, Jordan J. Karlitz, Elizabeth T. H. Fontham, Katherine P. Theall, Lu Zhang, Mei-Chin Hsieh, Lori A. Pollack, Xiao-Cheng Wu
Summary: Research on optimal relative dose intensity (RDI) of FOLFOX in stage III colon cancer by risk profiles is limited. This study identified the optimal RDI for high-risk and low-risk patients, finding that for high-risk patients, RDI as low as 70% did not significantly affect the risk of death, and for low-risk patients, RDI as low as 45% did not significantly affect the risk of death.
CLINICAL COLORECTAL CANCER
(2022)
Article
Medicine, Research & Experimental
Wei Chong, Xingyu Zhu, Huicheng Ren, Chunshui Ye, Kang Xu, Zhe Wang, Shengtao Jia, Liang Shang, Leping Li, Hao Chen
Summary: This study elucidates the molecular heterogeneity of KRAS-mutant CRC and reveals new biological subtypes and therapeutic possibilities for these tumors.
Article
Oncology
Yasir G. Malik, Lars Gustav Lyckander, Jonas C. Lindstrom, Olof Vinge-Holmquist, Ariba E. Sheikh, Johannes K. Schultz, Dejan Ignjatovic
Summary: This study compared the recurrence rates and survival of stage III colon cancer patients treated with or without adjuvant chemotherapy, and evaluated the impact of other prognostic factors on outcomes. The findings suggest that certain subgroups of patients with stage III colon cancer have good prognosis even without adjuvant chemotherapy, but further prospective trials are needed to determine the necessity of adjuvant chemotherapy.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
(2021)
Article
Oncology
Sarah Xinhui Tan, Yoanna Pumpalova, Alexandra M. M. Rogers, Kishan Bhatt, Candice-lee Herbst, Paul Ruff, Alfred I. I. Neugut, Chin Hur
Summary: This study evaluates the cost-effectiveness of adjuvant chemotherapy for high-risk stage II and stage III colon cancer treatment in South Africa and demonstrates how this analysis can inform cancer treatment recommendations in low- and middle-income countries.
Article
Oncology
Kjersti Elvestad Hestetun, Nina Benedikte Rosenlund, Luka Stanisavljevic, Olav Dahl, Mette Pernille Myklebust
Summary: Deficient mismatch repair (dMMR) is associated with improved prognosis in stage II colon cancer but not in stage III colon cancer.
FRONTIERS IN ONCOLOGY
(2022)
Article
Oncology
Yunxiao Liu, Hao Zhang, Yuliuming Wang, Chunlin Wang, Huan Xiong, Yang Wang, Haoyu Jing, Xia Jiang, Hanqing Hu, Qingchao Tang, Guiyu Wang
Summary: This study found that in stage III colon cancer, the status or number of tumor deposits (TD) (mpN and npN) may be superior to the positive lymph nodes (pN) stage in assessing prognosis, emphasizing the importance of including TD information in the pN stage.
FRONTIERS IN ONCOLOGY
(2022)
Article
Medicine, General & Internal
Devon J. Boyne, Winson Y. Cheung, Robert J. Hilsden, Tolulope T. Sajobi, Atul Batra, Christine M. Friedenreich, Darren R. Brenner
Summary: This study showed that explicit emulation of a target trial better approximated results from an analogous well-conducted randomized clinical trial. It suggests that a shortened duration of adjuvant chemotherapy may not significantly impact overall survival.
Article
Pharmacology & Pharmacy
Wen-Kuan Huang, Hung-Chih Hsu, Shu-Hao Chang, Wen-Chi Chou, Pei-Hung Chang, Sum-Fu Chiang, John Wen-Cheng Chang, Jen-Shi Chen, Tsai-Sheng Yang, Lai-Chu See
Summary: The real-world effectiveness of oxaliplatin in stage III colon cancer was not found to significantly improve survival rates. Future research should focus on identifying the specific subpopulations of patients who may benefit significantly from the addition of oxaliplatin.
FRONTIERS IN PHARMACOLOGY
(2021)
Article
Oncology
Charles S. Fuchs, Mustafa Ozguroglu, Yung-Jue Bang, Maria Di Bartolomeo, Mario Mandala, Min-Hee Ryu, Lorenzo Fornaro, Tomasz Olesinski, Christian Caglevic, Hyun C. Chung, Kei Muro, Eric Van Cutsem, Anneli Elme, Peter Thuss-Patience, Ian Chau, Atsushi Ohtsu, Pooja Bhagia, Anran Wang, Chie-Schin Shih, Kohei Shitara
Summary: In this long-term analysis, second-line pembrolizumab did not significantly improve overall survival but was associated with higher 24-month OS rates than paclitaxel in the CPS>=1 population. Pembrolizumab also increased overall survival benefit with PD-L1 enrichment among patients with PD-L1-positive gastric/GEJ cancer and led to fewer treatment-related adverse events (TRAEs) compared to paclitaxel.
Meeting Abstract
Oncology
Manish A. Shah, Jaffer A. Ajani, Salah-Eddin Al-Batran, Yung-Jue Bang, Daniel V. T. Catenacci, Peter C. Enzinger, David H. Ilson, Sunnie S. Kim, Florian Lordick, Kohei Shitara, Eric Van Cutsem, Ahsan Arozullah, Jeffrey J. Raizer, Jung Wook Park, Rui-hua Xu
JOURNAL OF CLINICAL ONCOLOGY
(2022)
Meeting Abstract
Oncology
Kensei Yamaguchi, Yung-Jue Bang, Satoru Iwasa, Naotoshi Sugimoto, Min-Hee Ryu, Daisuke Sakai, Hyun Cheol Cheol Chung, Hisato Kawakami, Hiroshi Yabusaki, Jeeyun Lee, Kaku Saito, Yoshinori Kawaguchi, Takahiro Kamio, Akihito Kojima, Masahiro Sugihara, Kohei Shitara
JOURNAL OF CLINICAL ONCOLOGY
(2022)
Article
Gastroenterology & Hepatology
Hye-Yeong Jin, Seung-Yeon Yoo, Ji-Ae Lee, Xianyu Wen, Younghoon Kim, Hye Eun Park, Yoonjin Kwak, Nam-Yun Cho, Jeong Mo Bae, Jung Ho Kim, Hye Seung Lee, Gyeong Hoon Kang
Summary: Tumor stroma and tumor-infiltrating lymphocytes (TILs) have different effects on the prognosis of colorectal cancer (CRC) patients. The combinatory statuses of tumor-stromal percentage (TSP) and TILs can provide powerful prognostic information for CRCs.
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY
(2022)
Article
Gastroenterology & Hepatology
Sang Sik Cho, Ji Won Park, Gyeong Hoon Kang, Jung Ho Kim, Jeong Mo Bae, Sae-Won Han, Tae-You Kim, Min Jung Kim, Seung-Bum Ryoo, Seung-Yong Jeong, Kyu Joo Park
Summary: This study aimed to determine whether the location of lymphatic invasion, vascular invasion, and perineural invasion could affect the survival of patients with stage II colon cancer. The results showed that extramural invasion was associated with a worse prognosis, while intramural invasion was not. Therefore, pathologic reports about the location of invasion may be helpful for predicting prognosis and determining the need for adjuvant chemotherapy in stage II colon cancers.
DISEASES OF THE COLON & RECTUM
(2023)
Article
Oncology
Tae Won Kim, Howard A. Burris, Maria J. de Miguel Luken, Michael J. Pishvaian, Yung-Jue Bang, Michael Gordon, Ahmad Awada, D. Ross Camidge, F. Stephen Hodi, Grant A. McArthur, Wilson H. Miller, Andres Cervantes, Laura Q. Chow, Alexander M. Lesokhin, Annemie Rutten, Mario Sznol, Deepali Rishipathak, Shang-Chiung Chen, Eric Stefanich, Tony Pourmohamad, Maria Anderson, Jeong Kim, Mahrukh Huseni, Ina Rhee, Lillian L. Siu
Summary: This study evaluated the first-in-human use of MOXR0916, a humanized monoclonal antibody, in the treatment of advanced solid tumors. The results showed that MOXR0916 was well tolerated and demonstrated evidence of tumor immune activation. Although objective responses were rare with monotherapy, further investigation in combination with PD-1/PD-L1 antagonists is warranted.
CLINICAL CANCER RESEARCH
(2022)
Article
Pathology
Minsun Jung, Ji Ae Lee, Seung-Yeon Yoo, Jeong Mo Bae, Gyeong Hoon Kang, Jung Ho Kim
Summary: This study investigates the spatial heterogeneity of tumor-infiltrating lymphocytes (TILs) in colorectal carcinomas (CRCs) and identifies its prognostic and immunologic significance. It demonstrates that TILs density and spatial distribution have a significant impact on prognosis in CRCs. TIL-low CRCs can be divided into two subgroups with distinct prognosis and immunologic characteristics based on the spatial heterogeneity of TILs. These findings suggest that the intratumoral spatial heterogeneity of TILs can be a key element for clinically relevant immunologic subtyping of tumors.
Meeting Abstract
Oncology
A. Italiano, A. Gazzah, J. Tabernero, Y-K. Kang, E. Calvo, M. Provencio Pulla, Y-J. Bang, F. Barlesi, P. L. Bedard, J. O. Park, J-S. Kim, M. Chadjaa, S. Yoruk, J-P. Delord
ANNALS OF ONCOLOGY
(2022)
Article
Oncology
Kensei Yamaguchi, Yung-Jue Bang, Satoru Iwasa, Naotoshi Sugimoto, Min-Hee Ryu, Daisuke Sakai, Hyun Cheol Chung, Hisato Kawakami, Hiroshi Yabusaki, Jeeyun Lee, Tatsu Shimoyama, Keun-Wook Lee, Kaku Saito, Yoshinori Kawaguchi, Takahiro Kamio, Akihito Kojima, Masahiro Sugihara, Kohei Shitara
Summary: This study aimed to investigate the efficacy and safety of trastuzumab deruxtecan (T-DXd) in patients with HER2-low gastric or gastroesophageal junction adenocarcinoma. The results showed that T-DXd has clinical activity in heavily pretreated patients with HER2-low gastric/GEJ adenocarcinoma.
JOURNAL OF CLINICAL ONCOLOGY
(2023)
Article
Oncology
Lyn Ley Lam, Nick Pavlakis, Kohei Shitara, Katrin M. Sjoquist, Andrew J. Martin, Sonia Yip, Yoon-Koo Kang, Yung-Jue Bang, Li-Tzong Chen, Markus Moehler, Tanios Bekaii-Saab, Thierry Alcindor, Christopher J. O'Callaghan, Niall C. Tebbutt, Wendy Hague, Howard Chan, Sun Young Rha, Keun-Wook Lee, Val Gebski, Anthony Jaworski, John Zalcberg, Timothy Price, John Simes, David Goldstein
Summary: This study aims to evaluate the efficacy and safety of regorafenib alone and in combination with nivolumab in advanced gastro-oesophageal cancer patients. The study consists of two international randomized controlled trials, comparing the efficacy of regorafenib versus placebo, and the efficacy of regorafenib plus nivolumab versus chemotherapy. The primary endpoint of the study is overall survival.
Article
Medicine, General & Internal
Kohei Shitara, Florian Lordick, Yung-Jue Bang, Peter Enzinger, David Ilson, Manish A. Shah, Eric Van Cutsem, Rui-Hua Xu, Giuseppe Aprile, Jianming Xu, Joseph Chao, Roberto Pazo-Cid, Yoon-Koo Kang, Jianning Yang, Diarmuid Moran, Pranob Bhattacharya, Ahsan Arozullah, Jung Wook Park, Mok Oh, Jaffer A. Ajani
Summary: Zolbetuximab in combination with mFOLFOX6 significantly prolongs progression-free survival and overall survival in patients with CLDN18.2-positive, HER2-negative, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma, with good safety profile.
Article
Biochemistry & Molecular Biology
Vivek Subbiah, Robert J. Kreitman, Zev A. Wainberg, Anas Gazzah, Ulrik Lassen, Alexander Stein, Patrick Y. Wen, Sascha Dietrich, Maja J. A. de Jonge, Jean-Yves Blay, Antoine Italiano, Kan Yonemori, Daniel C. Cho, Filip Y. F. L. de Vos, Philippe Moreau, Elena Elez Fernandez, Jan H. M. Schellens, Christoph C. Zielinski, Suman Redhu, Aislyn Boran, Vanessa Q. Passos, Palanichamy Ilankumaran, Yung-Jue Bang
Summary: This study is a phase 2 basket trial evaluating the efficacy and safety of dabrafenib plus trametinib in patients with BRAFV600E-mutated advanced rare cancers. The overall response rates in different tumor types ranged from 56% to 89%. Secondary endpoints included duration of response, progression-free survival, overall survival, and safety.
Article
Oncology
Fortunato Ciardiello, Yung-Jue Bang, Andres Cervantes, Mikhail Dvorkin, Charles D. Lopez, Jean-Philippe Metges, Antonio Sanchez Ruiz, Mariona Calvo, Andrew H. Strickland, George Kannourakis, Kei Muro, Hisato Kawakami, Jia Wei, Christophe Borg, Zhaoyin Zhu, Neal Gupta, Robert J. Pelham, Lin Shen
Summary: The study investigated the efficacy and safety of maintenance therapy with Pamiparib in gastric cancer. The results showed that Pamiparib did not demonstrate a significant superiority in progression-free survival (PFS) compared to placebo, but it was well tolerated with few adverse events.
Article
Biochemistry & Molecular Biology
Manish A. Shah, Kohei Shitara, Jaffer A. Ajani, Yung-Jue Bang, Peter Enzinger, David Ilson, Florian Lordick, Eric Van Cutsem, Javier Gallego Plazas, Jing Huang, Lin Shen, Sang Cheul Oh, Patrapim Sunpaweravong, Hwoei Fen Soo Hoo, Haci Mehmet Turk, Mok Oh, Jung Wook Park, Diarmuid Moran, Pranob Bhattacharya, Ahsan Arozullah, Rui-Hua Xu
Summary: The GLOW trial demonstrated that zolbetuximab, a monoclonal antibody targeting CLDN18.2, combined with CAPOX, significantly improved progression-free survival and overall survival in patients with CLDN18.2-positive, HER2-negative, locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma.
Article
Oncology
Younghoon Kim, Gyeong Hoon Kang, Haeryoung Kim
Summary: A systematic review and meta-analysis showed that the presence of heterologous component is associated with worse overall survival in gynecologic carcinosarcoma, but not with recurrence-free survival and disease-free survival.
JOURNAL OF GYNECOLOGIC ONCOLOGY
(2023)